Menu
Close
About ABRYSVO
Access & Support
86% vaccine efficacy against RSV-LRTD with ≥3 symptoms
(96.66% CI: 32.0, 98.7)6
67% vaccine efficacy against RSV-LRTD with ≥2 symptoms
(96.66% CI: 28.8, 85.8)6
‡Primary Analysis: The median duration of efficacy follow-up was 7 months. Evaluable efficacy population: ABRYSVO, n=16,306; placebo, n=16,308.6
The only RSV vaccine approved for both adults aged 60+ and pregnant individuals (at 32-36 weeks of gestation) for the protection of infants (from birth through 6 months) via maternal immunization6
Learn more about the maternal indication
ABRYSVO offers 2 needle-free§ options to fit your practice
Learn more about ABRYSVO® ACT-O-VIAL® and the ABRYSVO® Reconstitution Kit
§Needle required for intramuscular injection is not included.
Get the support you need and learn more about costs and coverage
Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.
Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.